Sökning: onr:"swepub:oai:DiVA.org:umu-140899" >
Re-treatment with r...
Re-treatment with radium-223 : first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
- Artikel/kapitelEngelska2017
Förlag, utgivningsår, omfång ...
-
OXFORD UNIV PRESS,2017
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-140899
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-140899URI
-
https://doi.org/10.1093/annonc/mdx331DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, patients usually develop disease progression after initial treatment. This prospective phase I/II study assessed re-treatment safety and efficacy of up to six additional radium-223 injections. Patients and methods: Patients had castration-resistant prostate cancer and bone metastases and six initial radium-223 injections with no on-treatment bone progression; all had subsequent radiologic or clinical progression. Concomitant agents were allowed at investigator discretion, excluding chemotherapy and initiation of new abiraterone or enzalutamide. The primary endpoint was safety; additional exploratory endpoints included time to radiographic bone progression, time to total alkaline phosphatase and prostate-specific antigen progression, radiographic progression-free survival, overall survival, time to first symptomatic skeletal event (SSE), SSE-free survival, and time to pain progression. Results: Among 44 patients, 29 (66%) received all six re-treatment injections. Median time from end of initial radium-223 treatment was 6 months. Forty-one (93%) reported >= 1 treatment-emergent adverse event. No grade 4-5 hematologic treatment-emergent adverse events occurred. Only one (2%) patient had radiographic bone progression; eight (18%) had radiographic soft tissue tumor progression (three lymph node and five visceral metastases). Median times to total alkaline phosphatase and prostate-specific antigen progression were not reached and 2.2 months, respectively. Median radiographic progression-free survival was 9.9 months (12.8-month maximum follow-up). Five (11%) patients died and eight (18%) experienced first SSEs. Median overall survival, time to first SSE, and SSE-free survival were not reached. Five (14%) of 36 evaluable patients (baseline worst pain score <= 7) had pain progression. After 2 years of follow-up, 28 (64%) patients died, and the median overall survival was 24.4 months. Conclusions: Re-treatment with a second course of six radium-223 injections after disease progression is well tolerated, with minimal hematologic toxicity and low radiographic bone progression rates in this small study with limited follow-up. Favorable safety and early effects on disease progression indicate that radium-223 re-treatment is feasible and warrants further evaluation in larger prospective trials.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Heinrich, D.
(författare)
-
Mariados, N.
(författare)
-
Mendez Vidal, M. J.
(författare)
-
Keizman, D.
(författare)
-
Thellenberg Karlsson, CamillaUmeå universitet,Institutionen för strålningsvetenskaper(Swepub:umu)cath0005
(författare)
-
Peer, A.
(författare)
-
Procopio, G.
(författare)
-
Frank, S. J.
(författare)
-
Pulkkanen, K.
(författare)
-
Rosenbaum, E.
(författare)
-
Severi, S.
(författare)
-
Trigo Perez, J. M.
(författare)
-
Wagner, V.
(författare)
-
Li, R.
(författare)
-
Nordquist, L. T.
(författare)
-
Umeå universitetInstitutionen för strålningsvetenskaper
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Annals of Oncology: OXFORD UNIV PRESS28:10, s. 2464-24710923-75341569-8041
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sartor, O.
-
Heinrich, D.
-
Mariados, N.
-
Mendez Vidal, M. ...
-
Keizman, D.
-
Thellenberg Karl ...
-
visa fler...
-
Peer, A.
-
Procopio, G.
-
Frank, S. J.
-
Pulkkanen, K.
-
Rosenbaum, E.
-
Severi, S.
-
Trigo Perez, J. ...
-
Wagner, V.
-
Li, R.
-
Nordquist, L. T.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Umeå universitet